\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesThe interrelated calls for pilot lines issued by the Chips JU are now open for submission.
The calls for pilot lines include:
The same application is submitted to those calls and the evaluation will consist of the simultaneous evaluation of the interrelated calls.
All calls are open for submission on the Funding & Tenders Portal:
Pilot line on advanced sub 2nm leading-edge system on chip technology
Pilot line on advanced Fully Depleted Silicon On Insulator technologies targeting 7nm
Pilot line on advanced Packaging and Heterogenous Integration
Pilot line on advanced semiconductor devices based on Wide Bandgap materials
Deadline for submission is 29 February 2024, 17.00 CET (Brussels time).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The EU introduced a new ICT Supply Chain Security Toolbox, providing an EU approach to identify, assess, and mitigate cybersecurity risks across ICT supply chains. The toolbox will help Member States and public and private actors to bolster the security of ICT supply chains in the EU as set out in the revised Cybersecurity Act presented... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
